Dubai, UAE – January 13, 2026 — Kings Research today announced the release of its latest market intelligence study, “Global Leukapheresis Market: Size, Share, Trends & Forecast 2025–2032.” The report presents a detailed assessment of market growth dynamics, technological advancements, segmentation trends, and the competitive landscape shaping the global leukapheresis industry.
According to Kings Research, the global leukapheresis market was valued at USD 103.4 million in 2024 and is projected to grow from USD 110.5 million in 2025 to USD 180.5 million by 2032, exhibiting a CAGR of 7.26% during the forecast period. Market expansion is driven by increasing use of leukapheresis in cell and gene therapies, rising oncology research, and growing demand for high-quality cellular material in clinical and commercial biopharmaceutical applications.
Leukapheresis is a specialized apheresis procedure used to separate and collect white blood cells from whole blood for therapeutic and research purposes. It is a critical process in the development and manufacturing of advanced therapies, including CAR-T cell therapies, immunotherapies, and stem cell-based treatments. Its importance is reinforced by the growing oncology burden and expanding cell therapy pipeline, with the U.S. alone recording over 1.9 million new invasive cancer cases in 2021, while leukemia remains a key hematologic malignancy requiring advanced cellular treatments.
As precision medicine and personalized therapies gain momentum, leukapheresis is becoming an essential component of modern clinical research and biomanufacturing workflows, particularly for autologous cell therapies where patient-derived leukocytes are the starting material.
Kings Research identifies the following growth accelerators:
1. Cell and Gene Therapy Development
Rising global investment in CAR-T and gene-modified therapies is increasing demand for reliable leukapheresis services and equipment. As of April 2024, approximately 1,580 CAR-T cell therapy clinical trials were registered globally on ClinicalTrials.gov, reflecting the rapid expansion of research programs that depend on leukapheresis for cell collection. In parallel, the U.S. Food and Drug Administration has approved six CAR-T cell therapies for hematologic cancers, all of which require leukapheresis as a foundational manufacturing step.
2. Oncology Research Expansion
Growing cancer prevalence and increased clinical trial activity are supporting higher utilization of leukapheresis in both research and therapeutic applications. In the United States, leukemia remains a significant indication, with approximately 3,800 new leukemia cases diagnosed annually among children and adolescents, underscoring sustained demand for advanced cellular and immunotherapies (Source: stacks.cdc.gov).
3. Biopharmaceutical Manufacturing Scale-Up
Contract development and manufacturing organizations are increasingly adopting standardized leukapheresis processes to ensure consistent cell quality and reproducibility. Clinical trial analyses indicate that CAR-T studies leading to regulatory approvals involved a median of approximately 108 patients per trial cohort undergoing leukapheresis, highlighting the procedural scale required to support late-stage development and commercialization (Source: pmc.ncbi.nlm.nih.gov).
4. Technological Advancements
Continuous innovation in apheresis systems is improving collection efficiency, patient safety, and process reproducibility.
For biopharmaceutical companies, clinical research organizations, and healthcare providers, the leukapheresis market offers clear strategic value:
- Therapy Enablement: High-quality leukapheresis is essential for the successful development and commercialization of cell and gene therapies.
- Operational Reliability: Advanced systems ensure consistent cell yields, improved process control, and reduced variability in clinical and manufacturing workflows.
- Scalability: Standardized leukapheresis platforms support transition from clinical trials to commercial-scale production.
- Research Acceleration: Reliable cell collection enhances study timelines and data quality across oncology and immunology research.
- Regulatory Alignment: Controlled and traceable processes support compliance with evolving regulatory standards in advanced therapeutics.
Regional Outlook
- North America: The region holds the largest share, supported by a strong biopharmaceutical ecosystem, a high concentration of cell therapy developers, and robust clinical trial activity. The U.S. continues to lead CAR-T research and approvals, reinforcing sustained demand for leukapheresis across academic centers and commercial manufacturing facilities.
- Asia-Pacific: Fastest-growing region, driven by expanding biomanufacturing capabilities, rising clinical trial activity, and increasing investments in regenerative medicine.
Competitive Landscape
The market is characterized by technological innovation, strategic collaborations, and capacity expansion. Key players operating in the leukapheresis market include Terumo Corporation, Fresenius Kabi USA, LLC, Haemonetics Corporation, Asahi Kasei Group, Miltenyi Biotec, Macopharma, B. Braun SE, Medica SPA, Charles River Laboratories, ZenBio, Inc., Adacyte Therapeutics, Sysmex Corporation, AllCells, Lonza Group AG, and Cerus Corporation.
The full Kings Research report provides in-depth segmentation analysis by product, application, end user, and region, along with competitive benchmarking and strategic insights. To request a sample, access the complete report, or explore customized consulting services, please visit https://www.kingsresearch.com/report/leukapheresis-market-3013.
About Kings Research
Kings Research is a global provider of syndicated market research reports and consulting services, supporting organizations in identifying emerging opportunities, evaluating competitive environments, and making informed, data-driven business decisions.
All market data are sourced from Kings Research proprietary analysis, validated against credible government publications and peer-reviewed research papers. Examples cited include U.S. National Institutes of Health, U.S. Food and Drug Administration, National Library of Medicine, World Health Organization, and European Medicines Agency.